Key result
In a pilot evaluation of 36 patients, NT-proBNP concentrations showed no significant differences between different antipsychotic groups over 21 days, though baseline variations were observed by age and cardiovascular history.
Why the study?
Does antipsychotic medication influence NT-proBNP concentration in patients initiating treatment?
Observational (n=36)
Assays were performed blind to clinical information
Yes
Does antipsychotic medication influence NT-proBNP concentration in patients initiating treatment?
Antipsychotic medication may influence plasma NT-proBNP concentrations, suggesting its potential utility as a biomarker for monitoring cardiovascular safety.
Answers are grounded in this paper and cite their sources.
No significant NT-proBNP change seen in this pilot; leaves open its value as antipsychotic safety marker pending larger studies.
BACKGROUND: The potential cardiotoxicity of antipsychotic drugs is well known. The N-terminal fragment of B-type natriuretic peptide (NT-proBNP) is considered to be a possible biomarker in clinical practice for the diagnosis and prognosis in patients with suspected heart failure. This pilot evaluation tests the influence of antipsychotic drugs on NT-proBNP concentration in view of the hypothesis that NT-proBNP could be used as marker for the tolerability and safety of antipsychotic medications. METHODS: On a routine basis, patient's blood samples were examined for NT-proBNP on days 0, 7 and 21 after initiation of a new antipsychotic monotherapy. All plasma samples were analysed for NT-proBNP using an electrochemiluminiscence immunoassay "ECLIA" (proBNP kit, Roche Diagnostics, Mannheim, Germany) on an Elecsys 2010 analyser. RESULTS: A difference was found in NT-proBNP values at day 0 between patients younger versus older than 40 years. Also women had comparatively lower NTproBNP on days 7 and 21. Smokers' levels of NT-proBNP values decreased more from day 0 to day 7. CONCLUSION: Our results suggest that antipsychotic medication influences the plasma concentration of NT-proBNP, suggesting a possible method to identify high-risk-patients for cardiovascular adverse effects due to antipsychotic medication. Larger studies should further test this hypothesis.
No takes yet. Share an insight, caveat, or question.
Kropp et al. (2005) conducted an observational in Schizophrenia, schizoaffective or affective disorder (n=36). Antipsychotic medication vs. Baseline (day 0) and between patient subgroups was evaluated on NT-proBNP concentration at days 0, 7, and 21. In a pilot evaluation of 36 patients, NT-proBNP concentrations showed no significant differences between different antipsychotic groups over 21 days, though baseline variations were observed by age and cardiovascular history.
Synapse has enriched 10 related papers. Consider them for comparative context: